# Liraglutide

```text
DRUG INFORMATION

  ADULT
    - Adult Patients : Initiate at 0.6 mg injected subcutaneously once daily for one
      week then increase to 1.2 mg daily.
      Source: US FDA label for liraglutide (Liraglutide), section 'dosage and
      administration', retrieved 2026-08-29
    - If additional glycemic control is required, increase the dose to 1.8 mg daily
      after one week of treatment with the 1.2 mg daily dose.
      Source: US FDA label for liraglutide (Liraglutide), section 'dosage and
      administration', retrieved 2026-08-29
    - If additional glycemic control is required increase the dose to 1.2 mg daily and
      if additional glycemic control is still required, increase the dose to 1.8 mg
      daily after at least one week of treatment with the 1.2 mg daily dose.
      Source: US FDA label for liraglutide (Liraglutide), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of liraglutide injection as an adjunct to diet and
      exercise to improve glycemic control in type 2 diabetes mellitus have been
      established in pediatric patients 10 years of age and older.
      Source: US FDA label for liraglutide (Liraglutide), section 'pediatric use',
      retrieved 2026-08-29
    - Adult Patients : Initiate at 0.6 mg injected subcutaneously once daily for one
      week then increase to 1.2 mg daily. If additional glycemic control is required,
      increase the dose to 1.8 mg daily after one week of treatment with the 1.2 mg
      daily dose. ( 2.1 ) Pediatric Patients : Initiate at 0.6 mg injected
      subcutaneously once daily for at least one week.
      Source: US FDA label for liraglutide (Liraglutide), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Pediatric Patients : Initiate at 0.6 mg injected subcutaneously once daily
      for at least one week.
      Source: US FDA label for liraglutide (Liraglutide), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No overall differences in safety or effectiveness for liraglutide injection have
      been observed between patients 65 years of age and older and younger patients. 8.6
      Renal Impairment No dose adjustment of liraglutide injection is recommended for
      patients with renal impairment [see Clinical Pharmacology ( 12.3 )].
      Source: US FDA label for liraglutide (Liraglutide), section 'use in specific
      populations', retrieved 2026-08-29
    - The safety and efficacy of liraglutide injection was evaluated in a 26-week
      clinical study that included patients with moderate renal impairment (eGFR 30 to
      60 mL/min/1.73 m 2 ) [see Clinical Studies ( 14.1 )].
      Source: US FDA label for liraglutide (Liraglutide), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - There is limited experience with liraglutide injection in patients with end stage
      renal disease. 8.7 Hepatic Impairment There is limited experience in patients with
      mild, moderate or severe hepatic impairment.
      Source: US FDA label for liraglutide (Liraglutide), section 'use in specific
      populations', retrieved 2026-08-29
    - No dose adjustment of liraglutide injection is recommended for patients with
      hepatic impairment [see Clinical Pharmacology ( 12.3 )] .
      Source: US FDA label for liraglutide (Liraglutide), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY   [ CAUTION ]
    The label allows it only when the benefit is judged to outweigh the risk. Read the
      quote below.
    - Risk Summary Based on animal reproduction studies, there may be risks to the fetus
      from exposure to liraglutide during pregnancy.
      Source: US FDA label for liraglutide (Liraglutide), section 'pregnancy', retrieved
      2026-08-29
    - Liraglutide injection should be used during pregnancy only if the potential
      benefit justifies the potential risk to the fetus.
      Source: US FDA label for liraglutide (Liraglutide), section 'pregnancy', retrieved
      2026-08-29
    - Animal reproduction studies identified increased adverse developmental outcomes
      from exposure during pregnancy.
      Source: US FDA label for liraglutide (Liraglutide), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Risk Summary There are no data on the presence of liraglutide in human milk, the
      effects on the breastfed infant, or the effects on milk production.
      Source: US FDA label for liraglutide (Liraglutide), section 'nursing mothers',
      retrieved 2026-08-29
    - Liraglutide was present in milk of lactating rats ( see Data) .
      Source: US FDA label for liraglutide (Liraglutide), section 'nursing mothers',
      retrieved 2026-08-29
    - Developmental and health benefits of breastfeeding should be considered along with
      the mother’s clinical need for liraglutide injection and any potential adverse
      effects on the breastfed infant from liraglutide or from the underlying maternal
      condition.
      Source: US FDA label for liraglutide (Liraglutide), section 'nursing mothers',
      retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)